Condition
Peritoneal Metastases From Gastric Cancer
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Recruiting2
Not Yet Recruiting1
Terminated1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07556640Phase 2Recruiting
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
NCT07313579Recruiting
Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
NCT07133490Phase 2Not Yet RecruitingPrimary
INTERACT Stomach-II
NCT03349827Not ApplicableTerminatedPrimary
HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer
Showing all 4 trials